Development of lecithinized superoxide dismutase as a drug for IPF

Tohru Mizushima

Research output: Contribution to journalArticle

Abstract

Idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) are thought to involve lung injury induced by reactive oxygen species (ROS), in particular superoxide anion. The enzyme, superoxide dismutase (SOD) catalyses the dismutation of superoxide anion to hydrogen peroxide. Lecithinized SOD (PC-SOD) has overcome a number of previous clinical limitations of SOD, including low tissue affinity and low stability in plasma. Recent animal studies suggest that PC-SOD is effective for the treatment of IPF and COPD. We are now performing the clinical study of PC-SOD for IPF patients.

Original languageEnglish
Pages (from-to)69-76
Number of pages8
JournalYakugaku Zasshi
Volume134
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Idiopathic Pulmonary Fibrosis
Superoxide Dismutase
Pharmaceutical Preparations
Superoxides
Chronic Obstructive Pulmonary Disease
Lung Injury
Hydrogen Peroxide
Reactive Oxygen Species
lecithinized superoxide dismutase
Enzymes

Keywords

  • Idiopathic pulmonary fibrosis
  • Reactive oxygen species
  • Superoxide dismutase

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Development of lecithinized superoxide dismutase as a drug for IPF. / Mizushima, Tohru.

In: Yakugaku Zasshi, Vol. 134, No. 1, 2014, p. 69-76.

Research output: Contribution to journalArticle

Mizushima, Tohru. / Development of lecithinized superoxide dismutase as a drug for IPF. In: Yakugaku Zasshi. 2014 ; Vol. 134, No. 1. pp. 69-76.
@article{a8c0e708d3af46d2bff575e75be78fd9,
title = "Development of lecithinized superoxide dismutase as a drug for IPF",
abstract = "Idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) are thought to involve lung injury induced by reactive oxygen species (ROS), in particular superoxide anion. The enzyme, superoxide dismutase (SOD) catalyses the dismutation of superoxide anion to hydrogen peroxide. Lecithinized SOD (PC-SOD) has overcome a number of previous clinical limitations of SOD, including low tissue affinity and low stability in plasma. Recent animal studies suggest that PC-SOD is effective for the treatment of IPF and COPD. We are now performing the clinical study of PC-SOD for IPF patients.",
keywords = "Idiopathic pulmonary fibrosis, Reactive oxygen species, Superoxide dismutase",
author = "Tohru Mizushima",
year = "2014",
doi = "10.1248/yakushi.13-00221-4",
language = "English",
volume = "134",
pages = "69--76",
journal = "Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan",
issn = "0031-6903",
publisher = "Pharmaceutical Society of Japan",
number = "1",

}

TY - JOUR

T1 - Development of lecithinized superoxide dismutase as a drug for IPF

AU - Mizushima, Tohru

PY - 2014

Y1 - 2014

N2 - Idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) are thought to involve lung injury induced by reactive oxygen species (ROS), in particular superoxide anion. The enzyme, superoxide dismutase (SOD) catalyses the dismutation of superoxide anion to hydrogen peroxide. Lecithinized SOD (PC-SOD) has overcome a number of previous clinical limitations of SOD, including low tissue affinity and low stability in plasma. Recent animal studies suggest that PC-SOD is effective for the treatment of IPF and COPD. We are now performing the clinical study of PC-SOD for IPF patients.

AB - Idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) are thought to involve lung injury induced by reactive oxygen species (ROS), in particular superoxide anion. The enzyme, superoxide dismutase (SOD) catalyses the dismutation of superoxide anion to hydrogen peroxide. Lecithinized SOD (PC-SOD) has overcome a number of previous clinical limitations of SOD, including low tissue affinity and low stability in plasma. Recent animal studies suggest that PC-SOD is effective for the treatment of IPF and COPD. We are now performing the clinical study of PC-SOD for IPF patients.

KW - Idiopathic pulmonary fibrosis

KW - Reactive oxygen species

KW - Superoxide dismutase

UR - http://www.scopus.com/inward/record.url?scp=84891643292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891643292&partnerID=8YFLogxK

U2 - 10.1248/yakushi.13-00221-4

DO - 10.1248/yakushi.13-00221-4

M3 - Article

C2 - 24389620

AN - SCOPUS:84891643292

VL - 134

SP - 69

EP - 76

JO - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

JF - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

SN - 0031-6903

IS - 1

ER -